Cardiovascular risk markers in geriatric patients: focus on lipoprotein associated phospholipase A₂

Czech version

Authors: J. Fortunato; P. Skořepa; M. Fortunato ¹; V. Bláha
Published in: Geriatrie a Gerontologie 2018, 7, č. 2: 68-71
Category: Review Article

Overview

The leading cause of death in developed countries are still complications of cardiovascular diseases. Atherosclerosis is one of the main risk factors and the main pathophysiological mechanism of these diseases. It is thus of paramount importance to identify potential risk factors of atherosclerosis at early stages, or even as a part of primary prevention of cardiovascular diseases. In the past years many new markers were explored, however their value in the context of clinical praxis (risk stratification, therapeutic interventions…) is still questionable. This paper tries to elucidate on the available methods to examine atherosclerosis, focusing especially on the geriatric population, where this issue is very common.

Keywords:
markers – phospholipase A₂

Sources

1. Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study. JAMA 1972: 221(7): 661–666.

2. Kannel WB, Castelli WP, McNamara PM et al. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 1972. 287(16): 781–787.

3. Bambrick P, Tan WS, Mulcahy R, et al. Vascular risk assessment in older adults without a history of cardiovascular disease. Exp Gerontol 2016; 79: 37–45.

4. Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action. J Am Med Dir Assoc 2013; 14: 392–7.

5. Finn M, Green P. The Application of Frailty to the Modern Cardiac Risk Assessment: a Case-Based Review. Curr Cardiovasc Risk Rep 2015; 9.

6. Schoenenberger AW, Stortecky S, Neumann S, et al. Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J 2013; 34: 684–92.

7. Sündermann S, Dademasch A, Rastan A, et al. One-year follow-up of patients undergoing elective cardiac surgery assessed with the Comprehensive Assessment of Frailty test and its simplified form. Interact Cardiovasc Thorac Surg 2011; 13: 119–123; discussion 123.

8. Singh M, Rihal CS, Lennon RJ, et al. Influence of frailty and health status on outcomes in patients with coronary disease undergoing percutaneous revascularization. Circ Cardiovasc Qual Outcomes 2011; 4: 496–502.

9. Filipovský J, et al. Summary of 2013 ESH/ESC Guidelines for the management of arterial hypertension. Prepared by the Czech Society of Hypertension/Czech Society of Cardiology, Cor et Vasa 56 (2014) e494–e518

10. Erbel R, Möhlenkamp S, Jöckel K-H, et al. Cardiovascular risk factors and signs of subclinical atherosclerosis in the Heinz Nixdorf Recall Study. Dtsch Arztebl Int 2008; 105: 1–8.

11. Matsushita K, Ballew SH, Sang Y, et al. Ankle-brachial index and physical function in older individuals: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2017; 257: 208–15.

12. Sillesen H, Fuster V. Predicting coronary heart disease: from Framingham Risk Score to ultrasound bioimaging. Mt Sinai J Med 2012; 79: 654–63.

13. Wu M-H, Chern M-S, Chen L-C, et al. Electron beam computed tomography evidence of aortic calcification as an independent determinant of coronary artery calcification. J Chin Med Assoc 2006; 69: 409–14.

14. Chiha J, Mitchell P, Gopinath B, et al. Prediction of Coronary Artery Disease Extent and Severity Using Pulse Wave Velocity. PLoS ONE 2016; 11: e0168598.

15. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a ‘set up’ for vascular disease. Circulation 2003; 107: 139–46.

16. Mitchell GF, Parise H, Vita JA, et al. Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension 2004; 44: 134–9.

17. Donato AJ, Morgan RG, Walker AE, et al. Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol 2015; 89: 122–35.

18. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol 1997; 20: II-11–17.

19. Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729–40.

20. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458–60.

21. Nordfjäll K, Eliasson M, Stegmayr B, et al. Telomere length is associated with obesity parameters but with a gender difference. Obesity (Silver Spring) 2008; 16: 2682–9.

22. Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005; 366: 662–4.

23. Cesari M, Penninx BWJH, Newman AB, et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 2003; 92: 522–8.

24. Lesniewski LA, Durrant JR, Connell ML, et al. Salicylate treatment improves age-associated vascular endothelial dysfunction: potential role of nuclear factor kappaB and forkhead Box O phosphorylation. J Gerontol A Biol Sci Med Sci 2011; 66: 409–18.

25. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005; 112: 25–31.

26. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 496–507.

27. Hui DY. Phospholipase A2 enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol 2012; 23: 235–40.

28. Fortunato J, Bláha V, Bis J, et al. Lipoprotein-associated phospholipase A₂ mass level is increased in elderly subjects with type 2 diabetes mellitus. J Diabetes Res 2014; 2014: 278063.

29. Colley KJ, Wolfert RL, Cobble ME. Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk. The EPMA Journal 2011; 2: 27–38.

30. Brilakis ES, Khera A, McGuire DK, et al. Influence of Race and Sex on Lipoprotein-Associated Phospholipase A2 Levels: Observations from the Dallas Heart Study. Atherosclerosis 2008; 199: 110–5.